ATE310505T1 - Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität - Google Patents
Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivitätInfo
- Publication number
- ATE310505T1 ATE310505T1 AT97923650T AT97923650T ATE310505T1 AT E310505 T1 ATE310505 T1 AT E310505T1 AT 97923650 T AT97923650 T AT 97923650T AT 97923650 T AT97923650 T AT 97923650T AT E310505 T1 ATE310505 T1 AT E310505T1
- Authority
- AT
- Austria
- Prior art keywords
- antineoplaston
- antineoplastic activity
- liposomal formulations
- intracellular
- compounds
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 6
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 abstract 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 230000003833 cell viability Effects 0.000 abstract 2
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 230000037041 intracellular level Effects 0.000 abstract 2
- 229940049953 phenylacetate Drugs 0.000 abstract 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 abstract 2
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical compound O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 abstract 2
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000010189 intracellular transport Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1761696P | 1996-05-14 | 1996-05-14 | |
| PCT/US1997/008167 WO1997042939A1 (en) | 1996-05-14 | 1997-05-14 | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
| US08/856,133 US6013278A (en) | 1996-05-14 | 1997-05-14 | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310505T1 true ATE310505T1 (de) | 2005-12-15 |
Family
ID=26690108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97923650T ATE310505T1 (de) | 1996-05-14 | 1997-05-14 | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6013278A (de) |
| EP (1) | EP0906088B1 (de) |
| JP (1) | JP4320052B2 (de) |
| AT (1) | ATE310505T1 (de) |
| CA (1) | CA2254772C (de) |
| DE (1) | DE69734713T2 (de) |
| WO (1) | WO1997042939A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258849B1 (en) * | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| US20020073441A1 (en) | 2000-12-13 | 2002-06-13 | Ross Brian D. | Compositions and methods for detecting proteolytic activity |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| EP1857112B1 (de) * | 2005-03-09 | 2013-05-15 | Sunstar Inc. | Mittel gegen krebs mit phytosterol-haltigen liposomen |
| US10624869B2 (en) * | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3071972D1 (en) * | 1979-11-02 | 1987-06-25 | Theurer Karl | Process for concentration of tumor-inhibiting substances |
| US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5231112A (en) * | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4663167A (en) * | 1984-04-16 | 1987-05-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| US4766046A (en) * | 1985-09-27 | 1988-08-23 | Liposome Technology, Inc. | Stabilized liposome/amphotericin composition and method |
| IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
| US5811119A (en) * | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
| EP0397774A1 (de) * | 1988-02-04 | 1990-11-22 | Board Of Regents, The University Of Texas System | Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten |
| FR2628317B1 (fr) * | 1988-03-09 | 1991-11-08 | Lvmh Rech | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de scutellaria, ou au moins un flavonoide tel que baicaleine ou baicaline et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite anti-allergique, anti-inflammatoire ou anti-vieillissement, l'incorporant |
| PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| US5194266A (en) * | 1989-08-08 | 1993-03-16 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition and method |
| AU7742491A (en) * | 1990-04-12 | 1991-11-11 | Stereo-Chemical Genetics, Inc. | Synthetic piperidinediones with cytostatic activity |
| US5238947A (en) * | 1990-04-12 | 1993-08-24 | University Of Georgia Research Foundation, Inc. | Synthetic piperidinediones with cytostatic activity |
| US5089508A (en) * | 1990-09-04 | 1992-02-18 | Burzynski Stanislaw R | Methods for treating aids |
| US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
| US5116622A (en) * | 1990-09-12 | 1992-05-26 | Burzynski Stanislaw R | Methods for treating parkinson's disease |
-
1997
- 1997-05-14 US US08/856,133 patent/US6013278A/en not_active Expired - Fee Related
- 1997-05-14 JP JP54110397A patent/JP4320052B2/ja not_active Expired - Lifetime
- 1997-05-14 AT AT97923650T patent/ATE310505T1/de not_active IP Right Cessation
- 1997-05-14 DE DE69734713T patent/DE69734713T2/de not_active Expired - Lifetime
- 1997-05-14 CA CA002254772A patent/CA2254772C/en not_active Expired - Fee Related
- 1997-05-14 WO PCT/US1997/008167 patent/WO1997042939A1/en active IP Right Grant
- 1997-05-14 EP EP97923650A patent/EP0906088B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69734713T2 (de) | 2006-07-06 |
| WO1997042939A1 (en) | 1997-11-20 |
| JP2002503209A (ja) | 2002-01-29 |
| DE69734713D1 (de) | 2005-12-29 |
| CA2254772A1 (en) | 1997-11-20 |
| US6013278A (en) | 2000-01-11 |
| JP4320052B2 (ja) | 2009-08-26 |
| EP0906088A1 (de) | 1999-04-07 |
| EP0906088B1 (de) | 2005-11-23 |
| CA2254772C (en) | 2004-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9700552A (es) | Conjugados de vitamina b12 y proteinas. | |
| SG43037A1 (en) | New esters of bi-and tricyclic aminoalcohols their preparation and their use in pharmaceutical compositions | |
| WO1998058629A3 (en) | Preparation of pharmaceutical compositions | |
| EP0783299A4 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe | |
| HU9503141D0 (en) | A method of enhancing cellular production molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | |
| SE8702907D0 (sv) | Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same | |
| DE69824622D1 (de) | Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen | |
| GEP20002032B (en) | (54) Pyrido[2,3-d]Pyrimidines and Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Composition Comprising Them and Methods of Treatment | |
| EP0523189A4 (de) | ||
| TR199802762T2 (xx) | Y�ksek miktarda ila� i�eren, h�zl� par�alanan ve h�zl� eriyen bile�imlerin haz�rlanmas� i�in gran�lat. | |
| MY105121A (en) | Pharmaceutical composition for systemic transdermal administration. | |
| ES2002140A6 (es) | Procedimiento para producir preparados de derivados de acido arilpropionico resorbibles por via transdermal y acuosos | |
| RU94035739A (ru) | Фармацевтическая композиция, содержащая нифедипин, и способ ее получения | |
| HUT75513A (en) | Taxane class derivative based pharmaceutical compositions and their preparation | |
| DK0666762T3 (da) | Fremgangsmåde til fremstilling af lipid-konjugater | |
| MC2289A1 (fr) | Composes heterocycliques | |
| BR9611571B1 (pt) | composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal. | |
| ATE310505T1 (de) | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität | |
| FR2699176B1 (fr) | Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. | |
| TW372193B (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient | |
| ES2018919A6 (es) | Procedimiento de obtencion de una composicion para promover el crecimiento de ganado porcino. | |
| ES8800040A1 (es) | Procedimiento para la obtencion de una composicion farmaceutica de liberacion retardada a base de 9,10-dihidro-alcaloides. | |
| ES8200678A1 (es) | Un procedimiento para la produccion de 10-(4-piperidinil)-10, 11-dihidro-dibenzo b,f 1,4 oxarepinas; tiazepinas y diaze-pinas. | |
| ATE212550T1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| CA2255856A1 (en) | Therapeutic uses for an aminosterol compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |